|
1
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22(61)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lyons TG: Targeted therapies for
triple-negative breast cancer. Curr Treat Options Oncol.
20(82)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kwapisz D: Pembrolizumab and atezolizumab
in triple-negative breast cancer. Cancer Immunol Immunother.
70:607–617. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Borri F and Granaglia A: Pathology of
triple negative breast cancer. Semin Cancer Biol. 72:136–145.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nagini S: Breast Cancer: Current molecular
therapeutic targets and new players. Anticancer Agents Med Chem.
17:152–163. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li J, Ma M, Yang X, Zhang M, Luo J, Zhou
H, Huang N, Xiao F, Lai B, Lv W and Zhang N: Circular HER2 RNA
positive triple negative breast cancer is sensitive to Pertuzumab.
Mol Cancer. 19(142)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bridges MC, Daulagala AC and Kourtidis A:
LNCcation: lncRNA localization and function. J Cell Biol.
220(e202009045)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kong S, Tao M, Shen X and Ju S:
Translatable circRNAs and lncRNAs: Driving mechanisms and functions
of their translation products. Cancer Lett. 483:59–65.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhao W, Geng D, Li S, Chen Z and Sun M:
LncRNA HOTAIR influences cell growth, migration, invasion, and
apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer
Med. 7:842–855. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xiu B, Chi Y, Liu L, Chi W, Zhang Q, Chen
J, Guo R, Si J, Li L, Xue J, et al: LINC02273 drives breast cancer
metastasis by epigenetically increasing AGR2 transcription. Mol
Cancer. 18(187)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang X, Zhao Z, Han X, Zhang Y, Zhang Y,
Li F and Li H: Single-Nucleotide polymorphisms promote
dysregulation activation by essential gene mediated bio-molecular
interaction in breast cancer. Front Oncol.
11(791943)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sabit H, Cevik E, Tombuloglu H,
Abdel-Ghany S, Tombuloglu G and Esteller M: Triple negative breast
cancer in the era of miRNA. Crit Rev Oncol Hematol.
157(103196)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bernardo BC, Ooi JY, Lin RC and McMullen
JR: miRNA therapeutics: A new class of drugs with potential
therapeutic applications in the heart. Future Med Chem.
7:1771–1792. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liang Y, Song X, Li Y, Chen B, Zhao W,
Wang L, Zhang H, Liu Y, Han D, Zhang N, et al: LncRNA BCRT1
promotes breast cancer progression by targeting miR-1303/PTBP3
axis. Mol Cancer. 19(85)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fan CN, Ma L and Liu N: Systematic
analysis of lncRNA-miRNA-mRNA competing endogenous RNA network
identifies four-lncRNA signature as a prognostic biomarker for
breast cancer. J Transl Med. 16(264)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xu M, Zhang J, Lu X, Liu F, Shi S and Deng
X: MiR-199a-5p-Regulated SMARCA4 promotes oral squamous cell
carcinoma tumorigenesis. Int J Mol Sci. 24(4756)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu L, Wu H, Pan J, Chen Z and Du L:
Significance of lncRNA CDKN2B-AS1 in Interventional therapy of
liver cancer and the mechanism under its participation in tumour
cell growth via miR-199a-5p. J Oncol. 2022(2313416)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang Q, Li G, Ma X, Liu L, Liu J, Yin Y,
Li H, Chen Y, Zhang X, Zhang L, et al: LncRNA TINCR impairs the
efficacy of immunotherapy against breast cancer by recruiting DNMT1
and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1
axis. Cell Death Dis. 14(76)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhuang X, Tong H, Ding Y, Wu L, Cai J, Si
Y, Zhang H and Shen M: Long noncoding RNA ABHD11-AS1 functions as a
competing endogenous RNA to regulate papillary thyroid cancer
progression by miR-199a-5p/SLC1A5 axis. Cell Death Dis.
10(620)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
S P: Thermal imaging techniques for breast
screening-a survey. Curr Med Imaging. 16:855–862. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q,
Qin Q, Zhao L, Huang Q, Luo Z, et al: Long noncoding RNA LINC00511
contributes to breast cancer tumourigenesis and stemness by
inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res.
37(289)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cedro-Tanda A, Ríos-Romero M,
Romero-Córdoba S, Cisneros-Villanueva M, Rebollar-Vega RG,
Alfaro-Ruiz LA, Jiménez-Morales S, Domínguez-Reyes C,
Villegas-Carlos F, Tenorio-Torres A, et al: A lncRNA landscape in
breast cancer reveals a potential role for AC009283.1 in
proliferation and apoptosis in HER2-enriched subtype. Sci Rep.
10(13146)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lin X, Dinglin X, Cao S, Zheng S, Wu C,
Chen W, Li Q, Hu Q, Zheng F, Wu Z, et al: Enhancer-Driven lncRNA
BDNF-AS induces endocrine resistance and malignant progression of
breast cancer through the RNH1/TRIM21/mTOR Cascade. Cell Rep.
31(107753)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zheng S, Yang L, Zou Y, Liang JY, Liu P,
Gao G, Yang A, Tang H and Xie X: Long non-coding RNA HUMT
hypomethylation promotes lymphangiogenesis and metastasis via
activating FOXK1 transcription in triple-negative breast cancer. J
Hematol Oncol. 13(17)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zheng C, Yan S, Lu L, Yao H, He G, Chen S,
Li Y, Peng X, Cheng Z, Wu M, et al: Lovastatin Inhibits EMT and
metastasis of triple-negative breast cancer stem cells through
dysregulation of cytoskeleton-associated proteins. Front Oncol.
11(656687)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Luo J, Yao JF, Deng XF, Zheng XD, Jia M,
Wang YQ, Huang Y and Zhu JH: 14, 15-EET induces breast cancer cell
EMT and cisplatin resistance by up-regulating integrin αvβ3 and
activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res.
37(23)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Leng X, Huang G, Li S, Yao M, Ding J and
Ma F: Correlation of breast cancer microcirculation construction
with tumor stem cells (CSCs) and epithelial-mesenchymal transition
(EMT) based on contrast-enhanced ultrasound (CEUS). PLoS One.
16(e0261138)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kumar D, Patel SA, Hassan MK, Mohapatra N,
Pattanaik N and Dixit M: Reduced IQGAP2 expression promotes EMT and
inhibits apoptosis by modulating the MEK-ERK and p38 signaling in
breast cancer irrespective of ER status. Cell Death Dis.
12(389)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kashyap A, Umar SM, Dev JR and Prasad CP:
Dihydrotanshinone-I modulates epithelial mesenchymal transition
(EMT) thereby impairing migration and clonogenicity of triple
negative breast cancer cells. Asian Pac J Cancer Prev.
22:2177–2184. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang Q, Li T, Wang Z, Kuang X, Shao N and
Lin Y: lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through
activating IGF-1/IGF-1R/ERK pathway. J Cell Mol Med. 24:8236–8247.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z
and Wang J: LncRNA GATA3-AS1 facilitates tumour progression and
immune escape in triple-negative breast cancer through
destabilization of GATA3 but stabilization of PD-L1. Cell Prolif.
53(e12855)2020.PubMed/NCBI View Article : Google Scholar
|
